Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies. 1 Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK. 2 Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers; 3 however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development. To this end, we developed an Escherichia coliederived rhNGF formulation that demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in healthy volunteers. 4 We report phase I results of topical rhNGF for patients with moderate-to-severe NK.
NGF0212/REPARO (Latin, "repair") was a phase I/II randomized, double-masked, multicenter, vehicle-controlled, parallel group study (ClinicalTrials.gov identifier NCT01756456) that evaluated the safety and efficacy of rhNGF eye drops (10 or 20 mg/ml, 6 drops/day for 8 weeks) in patients with moderate (stage 2) or severe (stage 3) NK.
Patients aged !18 years with stage 2 or 3 NK were enrolled according to published diagnostic criteria and inclusion/exclusion criteria described in the REPARO phase II report. 5 Table 1 summarizes patient demographics, baseline characteristics, and prior NK treatments.
Eighteen phase I patients (2 cohorts of 9 consecutively enrolled patients each) with stage 2 or 3 NK gave informed consent and were randomized 7:2 to rhNGF 10 mg/ml versus vehicle (cohort A) or rhNGF 20 mg/ml versus vehicle (cohort B). Sample size was based on clinical feasibility (i.e., no formal power calculation was performed), because phase I aimed primarily to assess the safety and systemic absorption of topical rhNGF to support proceeding with phase II, which was conducted, analyzed, and reported separately. 5 Patients, investigators, and site/sponsor staff were masked to primary randomized treatment. Indistinguishable treatment kits were randomly assigned by Statistical Analysis System programmers. A clinical research organization maintained the masked database. No formal statistical testing was applied to phase I data.
The study obtained institutional review board and independent ethics committee approval (detailed in the phase II report 5 ) and complied with the Declaration of Helsinki, Code of Federal Regulations, and Good Laboratory/Clinical Practice guidelines. Figure S1 (available at www.aaojournal.org) depicts overall study design and patient disposition, including reasons for withdrawal. The study included an 8-week controlled treatment period and a 48-or 56-week follow-up (duration determined by treatment allocation and corneal healing status during controlled treatment). In the event of treatment failure during the 8-week controlled treatment period (predefined as failure to achieve corneal healing, recurrence of NK after healing, or deterioration as described in the phase II report 5 ), vehicle-treated patients were eligible to receive 8 weeks of uncontrolled rhNGF treatment (cohort A: 10 mg/ml; cohort B: 20 mg/ml) before continuing followup (total follow-up: 56 weeks). However, no phase I patients entered the 56-week follow-up period.
The primary safety variable was incidence of adverse events (AEs), defined per Good Clinical Practice guidelines as any untoward medical occurrences in patients who received study treatment, regardless of causal or temporal association. Other safety parameters included visual analogue scale for ocular tolerability (described in the phase II report 5 ), best-corrected distance visual acuity measured in Early Treatment Diabetic Retinopathy Study letters, intraocular pressure, dilated fundus ophthalmoscopy, vital signs, hematology, and clinical chemistry. Table 1 summarizes treatment-related AEs (TAEs), defined as AEs recorded by the investigator as having possible, probable, or highly probable relationships to study treatment, during controlled treatment. Eye pain and headache were the most frequently reported TAEs during controlled treatment, each occurring in 2 patients (28.6%) in the rhNGF 20 mg/ml group. Treatment-related AEs reported during controlled treatment occurred in 1 of 18 patients each. No TAEs were reported during the 48-week follow-up. No deaths occurred during controlled treatment or follow-up, nor were there any notable trends or clinically significant differences over time or between treatment groups in laboratory parameters, vital signs, or other ocular safety assessments.
Pharmacokinetics (PK) profiling was performed as described previously. 4 As shown in Figure S2 (available at www.aaojournal.org), only 2 patients had detectable serum NGF at any time point. Of note, the patient in the rhNGF 10 mg/ml group had only 1 positive NGF measurement during the study, and the patient in the rhNGF 20 mg/ml group had detectable serum NGF levels at all time points, even before initiating study treatment. Taken together, the PK results suggest individual fluctuations of endogenous NGF independent of study treatment.
Although the phase I study was not designed or powered for efficacy outcomes, corneal healing (<0.5 mm fluorescein staining in the lesion area) was assessed in clinical pictures by central readers (masked to treatment assignment and duration) at week 4 (primary end point) and week 8 (key secondary end point). At week 4, based on postbaseline last-observation-carried-forward analysis, corneal healing was achieved by 1 of 4 patients (25.0%) receiving vehicle, 3 of 7 patients (42.9%) receiving rhNGF 10 mg/ml, and 3 of 7 patients (42.9%) receiving rhNGF 20 mg/ml. Of patients with responses available at week 8, corneal healing was achieved by 1 of 2 patients (50%) receiving vehicle, 4 of 6 patients (66.7%) receiving rhNGF 10 mg/ml, and 6 of 7 patients (85.7%) receiving rhNGF 20 mg/ml. No phase I patients discontinued because of a lack of efficacy or inadequate control of NK. Before week 8, no patients in any treatment group experienced deterioration. At week 8, 1 patient who received rhNGF 20 mg/ml experienced a decrease in best-corrected distance visual acuity score of >5 Early Treatment Diabetic Retinopathy Study letters.
The REPARO phase I study demonstrated that topical ophthalmic rhNGF (10 or 20 mg/ml), administered 6 drops/day for Patients may have received >1 prior treatment.
x Disease progression was defined as increase in lesion size !1 mm; decrease in best-corrected distance visual acuity by >5 Early Treatment Diabetic
Retinopathy Study letters; progression in lesion depth to corneal melting or perforation; or onset of infection. One patient in the rhNGF 10 mg/ml group had !1-mm increase in lesion size from baseline. k One patient in the rhNGF 20 mg/ml group had a transient decrease in blood pressure from baseline. 8 weeks, was well tolerated in patients with stage 2 or 3 NK. No safety concerns arose; most AEs were ocular, mild, and transient, and did not require discontinuing or corrective treatments. Most patients had undetectable serum NGF, and systemic AEs were infrequent and mild. This is consistent with previous PK findings in healthy volunteers 4 and lack of detectable systemic NGF or immunogenicity in the phase II study. 5 Taken together, these results suggest unlikely systemic absorption or accumulation of rhNGF. Favorable trends in corneal healing suggest that topical ophthalmic rhNGF may be effective for treating patients with moderate-to-severe NK. 
Collagen Cross-Linked Therapeutic Grafts in Fungal Keratitis
The management of fungal keratitis is challenging, and a recurrence of infection may be observed even after therapeutic keratoplasty (TPK). Collagen cross-linking (CXL) has antimicrobial and antikeratolytic properties and increasingly is being used in the treatment of infectious keratitis. 1, 2 Collagen cross-linkingetreated donor corneas used as carriers for the Boston keratoprosthesis have a decreased incidence of corneal melt. 3 The hypothesis of our study was that CXL-treated donor corneas may help to prevent the recurrence of infection in cases of fungal keratitis after TPK. We conducted a prospective interventional pilot study to evaluate the outcomes of TPK using CXL-treated donor corneas in fungal keratitis. Ethical clearance was obtained from the institutional review board at the All India Institute of Medical Sciences, New Delhi, India, and the study adhered to the tenets of Declaration of Helsinki. Written informed consent was obtained from all patients. Fifty-three eyes of 53 patients with fungal keratitis were randomized to undergo TPK with CXL-treated (group 1, n ¼ 26 eyes) or non-CXLetreated donor corneas (group 2, n ¼ 27 eyes). All patients 18 years of age or older with microbiologically proven (smear-or culture-positive results) fungal keratitis planned for TPK were included. Patients with coexistent viral or bacterial keratitis, endophthalmitis, a prior history of TPK, or systemic comorbidities were excluded. Comprehensive preoperative evaluation was performed. The donor corneoscleral buttons were mounted on an artificial chamber and cross-linked as per the Dresden protocol. Before surgery, the mean donor endothelial cell counts were 1582.5AE239.4 cells/mm 2 before CXL. After CXL, endothelial cell counts were not evaluated. Full-thickness penetrating keratoplasty was performed as per standard technique. Postoperative topical and systemic antifungals were prescribed. Topical corticosteroids were started after 2 weeks in patients with no recurrence of infection.
The primary outcome measure was the incidence of graft infection (recurrence of primary infection and new infections). Secondary outcome measures were graft clarity, visual acuity, deep vascularization of the graft, and complications such as persistent epithelial defect, graft rejection, corneal melt, suture-related problems, endophthalmitis, secondary glaucoma, and phthisis bulbi. Follow-up examinations were performed on day 1, day 7, month 1, month 3, and month 6. The data were analyzed using Stata software version 14.0 (StataCorp LP, College Station, TX), and a P value less than 0.05 was considered significant. 
